ZOMETA® Reduces Skeletal-Related Events From Bone Metastases In Prostate Cancer Patients

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumor types

Page

1 2

Skeletal fractures correlate with decreased survival in patients with
prostate cancer

Overall survival stratified by history of skeletal fracture⁵

ZOMETA® Increase in Survival Rate From Skeletal Fractures in Prostate Cancer Patients

Median overall survival was 121 and 160 months in men with and without a history of skeletal fracture since the diagnosis of prostate cancer, respectively (P=.004)⁵

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

Skeletal fractures correlate with decreased survival in patients with prostate cancer

Skeletal fractures correlate with decreased survival in patients with
prostate cancer